EyePoint, Inc. EYPT
Biotechnology: Laboratory Analytical Instruments · data as of November 13, 2026
EyePoint, Inc. (EYPT) is a industrial company listed in the US with a market value of about $35M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$343M, a net margin of -13281.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -41%.
About EyePoint
EyePoint is listed in the US and classified in biotechnology: laboratory analytical instruments. Revenue went from $27M in 2015 to $31M in 2025, growth of about 1.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 96% over three years (dilution for shareholders). It spends 705% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $31M | $43M | $46M | $41M | $37M | $34M | $20M | $5M | $8M | $2M |
| Net income | -$343M | -$232M | -$131M | -$71M | -$102M | -$58M | -$45M | -$57M | -$86M | -$18M | -$22M |
| Free cash flow | -$299M | -$243M | -$130M | -$2M | -$67M | -$50M | -$15M | -$57M | — | -$21M | -$16M |
| EPS (diluted) | $-3.97 | $-3.17 | $-2.32 | $-1.82 | $-2740.00 | $-2030.00 | $-3540.00 | $-5440.00 | $-12699.63 | $-5199.85 | $-6799.80 |
| Net margin | -13281.2% | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | -131.8% | -278.9% | -1884.2% | -245.2% | -1330.1% |
| ROIC | — | -58.5% | -32.0% | -21.8% | -69.8% | -24.7% | -62.8% | -81.2% | -55.8% | -139.3% | -103.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $8.31, 2617% above the current price; targets range from $0.50 to $31.00; the consensus rating is “Hold”; expected EPS is $-3.73 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does EyePoint pay a dividend?
Not currently.
Is EyePoint a good stock to buy?
We do not give buy or sell advice. EyePoint scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.